biotech
- Home
- biotech
Public
Research Note - Rise of the Cashless Economy
- Review
- June 3, 2020
Novatti launches new payments platform for purpose-issued Visa cards
- Review
- September 29, 2020
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
FDA approves Imugene to commence human trial for lung cancer immunotherapy
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read MorePublic
CLINUVEL to trial new drug addressing irreversible brain damage from by stroke
Leading pharmaceuticals company CLINUVEL (ASX: CUV) is set to commence human trials using the drug afamelanotide to dissolve or remove underlying blood clots in the brain that cause arterial ischaemic stroke (AIS) which accounts for 85% of the 15 million strokes suffered worldwide each year. Current stroke therapies are reliant on early intervention to restore
Read MorePublic
Telix submits FDA application for new prostate cancer imaging product
It may soon be easier for prostate cancer to be diagnosed at an early stage with Telix Pharmaceuticals (ASX: TLX) having submitted their radiopharmaceutical imaging technology to the Food and Drug Administration for approval. The New Drug Application (NDA) comes after completing clinical trials across more than 600 patients which builds on peer-reviewed clinical research
Read MorePublic
AusCann success with medicinal cannabis for nerve pain trials
Pharmaceuticals company AusCann (ASX: AC8) is set to progress to the next stage of clinical trials having successfully completed their first round on Neuvis, their cannabinoid-based capsule developed to treat nerve pain – an area of medicine that is inadequately met. Estimated to affect 7-10% of Australians, nerve pain is caused by damage to the
Read MorePublic
Alcidion secures major UK hospital network for Patientrack health monitoring
Smart healthcare continues to make strides in the United Kingdom with healthtech company Alcidion (ASX: ALC) to deploy their Patientrack monitoring system across the NHS Lanarkshire, the third largest health board in Scotland. With approximately 12,000 staff working across communities, health centres, clinics and three district hospitals, the 5-year agreement will see Alcidion roll out
Read MorePublic
Mayne Pharma strengthens oral contraceptives portfolio in lucrative U.S market
With the increasing competition amongst pharmaceutical companies being driven by a proliferation of generic brands, Mayne Pharma Group (ASX: MYX) has secured its position in the U.S as a leading oral contraceptives supplier by partnering with Novast Laboratories for 13 generic products. Of the 13 products, four have been approved by the U.S Food and
Read MorePublic